Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 8/20 | 0.62 |
| ▸ | PRSS2 | P07478 | 8/20 | 0.62 |
| ▸ | PRSS3 | P35030 | 8/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3652041 | 0.93 | PRSS1 (0.65) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL3661046 | 0.90 | PRSS1 (0.74) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL2920809 | 0.88 | PRSS1 (0.81) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL3671728 | 0.87 | PRSS1 (0.58) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL10279062 | 0.86 | PRSS1 (0.67) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL3654666 | 0.86 | PRSS1 (0.57) | PRSS1PRSS2PRSS3MAOAMAOB | |
| SCHEMBL3661866 | 0.84 | PRSS1 (0.64) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL3673660 | 0.84 | PRSS1 (0.61) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL3662216 | 0.84 | PRSS1 (0.65) | PRSS1PRSS2PRSS3NPY5RMAOA | |
| SCHEMBL3655376 | 0.84 | PRSS1 (0.65) | PRSS1PRSS2PRSS3NPY5RMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | COSTANZO MICHAEL J (US) | 2012-06-28 | — | — | US | disclosed |
| US-8158792-B2 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165327-A1 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
| US-20090163527-A1 | Spiropiperidines for use as tryptase inhibitors | TPSAB1, TPSB2, TPSD1 | PRSS1 7/4885PRSS2 33/4885PRSS3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.